Merrimack Pharmaceuticals Alpha and Beta Analysis
| MACKDelisted Stock | USD 11.96 0.12 1.01% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Merrimack Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Merrimack Pharmaceuticals over a specified time horizon. Remember, high Merrimack Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Merrimack Pharmaceuticals' market risk premium analysis include:
Beta (0.22) | Alpha (0.04) | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Merrimack |
Merrimack Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Merrimack Pharmaceuticals market risk premium is the additional return an investor will receive from holding Merrimack Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Merrimack Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Merrimack Pharmaceuticals' performance over market.| α | -0.04 | β | -0.22 |
Merrimack Pharmaceuticals Fundamentals Vs Peers
Comparing Merrimack Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Merrimack Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Merrimack Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Merrimack Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Merrimack Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Merrimack Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Merrimack Pharmaceuticals to competition |
| Fundamentals | Merrimack Pharmaceuticals | Peer Average |
| Return On Equity | -0.0112 | -0.31 |
| Return On Asset | -0.0107 | -0.14 |
| Current Valuation | (20.36 M) | 16.62 B |
| Shares Outstanding | 14.79 M | 571.82 M |
| Shares Owned By Insiders | 1.19 % | 10.09 % |
| Shares Owned By Institutions | 62.97 % | 39.21 % |
| Number Of Shares Shorted | 842.49 K | 4.71 M |
Merrimack Pharmaceuticals Opportunities
Merrimack Pharmaceuticals Return and Market Media
The Stock did not receive any noticable media coverage during the period. Price Growth (%) |
| Timeline |
About Merrimack Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Merrimack or other delisted stocks. Alpha measures the amount that position in Merrimack Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Merrimack Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Merrimack Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Merrimack Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Merrimack Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Merrimack Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Merrimack Pharmaceuticals' management manipulating its earnings.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Build Portfolio with Merrimack Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Consideration for investing in Merrimack Stock
If you are still planning to invest in Merrimack Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Merrimack Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |